Quintiles was among the first CROs to jump into risk-based clinical trial monitoring, and now the world's largest contract researcher is stretching out its platform, offering adaptive services that span the whole development process.
Icon, like most of the world's largest CROs, is investing in high-tech adaptive trial monitoring, and the company's latest offering allows investigators to comb through huge dumps of lab data in real time, tracking trial trends as they happen.
Irish CRO Icon is riding the spike in demand for adaptive trial monitoring, unveiling a new service that parses study data and highlights potential safety issues in real time.
PPD has acquired Pennsylvania's Acurian, folding the company's clinical trial patient enrollment and retention services into its expanding eClinical operation.
The FDA is encouraging drugmakers to embrace new methods of monitoring for clinical trials, and Icon is betting its latest offering can streamline how sponsors deal with study sites and save money in the process.
Now that the FDA is encouraging drugmakers to consider risk-based monitoring for clinical trials, CROs that have already invested in adaptive trials could stand to benefit.
As clinical trials get more and more complex, Pharmaceutical Product Development has reached out to technology consultancies Tessella and Berry Consultants to use FACTS, adaptive trial software that lets study designers simulate trials in their early planning stages.
Aptiv Solutions has grabbed a key piece to the tech puzzle it has been assembling to provide drug and device developers with adaptive clinical trials. The Reston, VA-based CRO, which launched last...